Emerging evidence indicates that the NOX2 inhibitor GSK2795039 attenuates doxorubicin-induced cardiotoxicity by suppressing NADPH oxidase-mediated oxidative stress and subsequent cardiomyocyte necroptosis, thereby improving myocardial remodeling and function in heart failure models [34]. Here, FMO5 is linked to heart failure.